Home
Live Updates
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript : comparemela.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
Related Keywords
Boston ,
Massachusetts ,
United States ,
China ,
Beijing ,
Japan ,
Tavo Espinoza ,
Amgen Kyprolis ,
Todd Davis ,
Paul Hadden ,
Matt Hewitt ,
Matthew Korenberg ,
Lawrence Solow ,
Primrose Bio ,
Merck Vaxneuvance ,
Karen Reeves ,
Mattew Korenberg ,
Matt Korenberg ,
Jazz Pharmaceuticals ,
Pfizer ,
Exchange Commission ,
Craig Hallum Capital Group ,
Amgen ,
Investment Committee ,
Ligand Pharmaceuticals Incorporated ,
Ligand Pharmaceuticals Inc ,
Call Transcript February ,
Pharmaceuticals Incorporated ,
Ligand Fourth Quarter ,
Chief Financial ,
Investor Relations ,
Private Securities Litigation Reform Act ,
Investor Day ,
Viking Therapeutics ,
Rich Baxter ,
Investment Operations ,
Drawbridge Special Opportunities Fund ,
Fortress Investment Group ,
Hayfin Capital Management ,
Clinical Strategy ,
Chief Medical Officer ,
Global Clinical Submissions ,
Pathios Therapeutics ,
Craig Hallum Capital ,
Travere European ,
comparemela.com © 2020. All Rights Reserved.